A pioneering technique designed to spot differences between immune cells in tumours could speed the development of cancer treatments, research suggests.
Scientists say the approach could be used to help doctors choose the best treatments for individual patients and predict which tumours are likely to respond to a particular therapy.
It could help target the use of immunotherapy - a new form of treatment that uses the body's own defences to tackle cancer.
This therapy has shown great promise in recent years, but identifying which patients will respond best is a challenge for doctors.
The new approach - based on gene analysis - makes it easier to spot the range of immune cells present in a tumour.
These cells could help the body detect and kill cancer when activated by certain drugs, scientists say.
Traditional treatments such as radiology do not discriminate between cell types and attack both cancerous and healthy cells, often leading to side-effects.
Researchers at the University of Edinburgh analysed genes from anonymised medical databases of thousands of tumours to identify genes associated with immune cells.
This allowed them to quickly detect immune cells in a tumour based on their genetic code even when they were mixed in with harmful cancerous cells and normal cells.
They say that this resource - called ImSig - paints the best picture of tumours to date and will allow scientists to study how certain immune cell types affect cancer growth.
In future, this could help doctors decide which patients were most likely to respond to immunotherapy, experts say.
Source: University of Edinburgh
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.